Wealth Alliance Grows Position in Hologic, Inc. (NASDAQ:HOLX)

Wealth Alliance grew its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,739 shares of the medical equipment provider’s stock after purchasing an additional 217 shares during the quarter. Wealth Alliance’s holdings in Hologic were worth $410,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Belpointe Asset Management LLC grew its position in Hologic by 18.0% during the 1st quarter. Belpointe Asset Management LLC now owns 937 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 143 shares during the last quarter. Deseret Mutual Benefit Administrators lifted its stake in shares of Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 155 shares during the period. Arizona State Retirement System lifted its stake in shares of Hologic by 0.3% in the 4th quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock valued at $4,810,000 after purchasing an additional 172 shares during the period. Cooper Financial Group lifted its stake in shares of Hologic by 1.9% in the 3rd quarter. Cooper Financial Group now owns 9,502 shares of the medical equipment provider’s stock valued at $659,000 after purchasing an additional 174 shares during the period. Finally, Kinneret Advisory LLC lifted its stake in shares of Hologic by 2.3% in the 1st quarter. Kinneret Advisory LLC now owns 7,867 shares of the medical equipment provider’s stock valued at $604,000 after purchasing an additional 176 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now directly owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Charles J. Dockendorff sold 1,465 shares of the firm’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the transaction, the chief financial officer now directly owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,846 shares of company stock valued at $2,473,443. Company insiders own 1.75% of the company’s stock.

Hologic Stock Performance

Shares of HOLX stock opened at $74.92 on Thursday. The firm has a market capitalization of $17.59 billion, a price-to-earnings ratio of 35.51, a price-to-earnings-growth ratio of 2.54 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The business has a fifty day moving average of $75.68 and a 200 day moving average of $72.48. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $87.88.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same period last year, the firm earned $1.07 EPS. As a group, research analysts expect that Hologic, Inc. will post 4.02 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of recent research reports. UBS Group lifted their price objective on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Wednesday, April 10th. William Blair reissued an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Finally, Evercore ISI lifted their price objective on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.